Work

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.5018

Authors: Daniel Peter Petrylak, Philip W. Kantoff, Anthony E. Mega, Nicholas J. Vogelzang, Joe Stephenson, Mark T. Fleming, Nancy Stambler, Michaela Petrini, Sara Blattman, Robert Joseph Israel

Institutions: Yale University, Dana-Farber Cancer Institute, Brown University, The US Oncology Network, Comprehensive Cancer Centers of Nevada, Virginia Oncology Associates, Progenics Pharmaceuticals (United States)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4250099557

Cites:

Cited by: 3

Related to: 10